Strs Ohio Sells 1,340 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Strs Ohio lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 31,656 shares of the biopharmaceutical company’s stock after selling 1,340 shares during the quarter. Strs Ohio’s holdings in Regeneron Pharmaceuticals were worth $24,459,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. WPG Advisers LLC boosted its position in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 25 shares during the period. SHP Wealth Management purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $26,000. Titan Wealth CI Ltd bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $29,000. Board of the Pension Protection Fund bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $31,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at about $31,000. 83.31% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the transaction, the director directly owned 17,503 shares of the company’s stock, valued at $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $654.27 on Friday. The firm has a market capitalization of $69.17 billion, a price-to-earnings ratio of 15.94, a PEG ratio of 1.44 and a beta of 0.24. The stock has a fifty day moving average of $652.48 and a 200 day moving average of $725.50. Regeneron Pharmaceuticals, Inc. has a 52 week low of $532.60 and a 52 week high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same period in the previous year, the firm earned $8.22 EPS. The company’s quarterly revenue was up 19.0% compared to the same quarter last year. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were paid a dividend of $0.94 per share. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Analyst Upgrades and Downgrades

REGN has been the topic of several recent research reports. Barclays reduced their price target on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Sanford C. Bernstein cut their target price on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Wells Fargo & Company decreased their target price on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a research note on Monday, May 18th. Canaccord Genuity Group dropped their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research report on Tuesday, May 19th. Finally, Truist Financial cut their price target on shares of Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $792.65.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.